Search results for "TRACT CANCER"

showing 10 items of 18 documents

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

AB052. P-20. Phase 2, open-label study of second-line M7824 treatment in patients with locally advanced or metastatic biliary tract cancer

2019

BACKGROUND: Transforming growth factor β (TGF-β) signaling promotes tumor immunosuppression; its inhibition in the tumor microenvironment may enhance the response to anti-PD-L1 treatment. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 mAb against PD-L1. Building upon encouraging efficacy observed in a phase 1 study, the present study will evaluate M7824 clinical benefit in patients with pretreated biliary tract cancer (BTC). METHODS: This multicenter, international trial is evaluating M7824 monotherapy in patients with locally advanced or metastatic (LA/M) BTC unselected for tumor PD-L1…

0301 basic medicineTumor microenvironmentBiliary tract cancerbiologybusiness.industrymedicine.drug_classMonoclonal antibodyFusion protein03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPD-L1Poster AbstractsCancer researchExtracellularbiology.proteinMedicineIn patientbusinessTransforming growth factor
researchProduct

Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer.

2011

Tobacco and alcohol are major risk factors for upper aerodigestive tract (UADT) cancer and significant variation is observed in UADT cancer rates across Europe. We have estimated the proportion of UADT cancer burden explained by tobacco and alcohol and how this varies with the incidence rates across Europe, cancer sub-site, gender and age. This should help estimate the minimum residual burden of other risk factors to UADT cancer, including human papillomavirus. We analysed 1981 UADT cancer cases and 1993 controls from the ARCAGE multicentre study. We estimated the population attributable risk (PAR) of tobacco alone, alcohol alone and their joint effect. Tobacco and alcohol together explaine…

AdultMaleCancer Researchmedicine.medical_specialtyAlcohol DrinkingEsophageal NeoplasmsAlcoholchemistry.chemical_compoundRisk FactorsTobaccomedicineHumansPopulation attributable riskGynecologyMouth neoplasmbusiness.industryIncidenceMedicine (all)Incidence (epidemiology)SmokingCase-control studyCancerAlcohol; ARCAGE study; Population attributable risk; Tobacco; Upper aerodigestive tract cancer; Adult; Alcohol Drinking; Case-Control Studies; Esophageal Neoplasms; Europe; Female; Humans; Incidence; Male; Middle Aged; Mouth Neoplasms; Otorhinolaryngologic Neoplasms; Risk Factors; Smoking; Oral Surgery; Medicine (all); Oncology; Cancer ResearchMiddle Agedmedicine.diseaseUpper aerodigestive tract cancerARCAGE studyEuropeOtorhinolaryngologic NeoplasmsUpper aerodigestive tractOncologychemistryCase-Control StudiesAttributable riskFemaleMouth NeoplasmsUpper aerodigestive tract cancer; ARCAGE study; Population attributable risk; Tobacco; AlcoholOral SurgeryAlcoholbusinessOropharyngeal CancersDemography
researchProduct

Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999- 2007: Results…

2015

Abstract Background The EUROCARE study collects and analyses survival data from population-based cancer registries (CRs) in Europe in order to provide data on between-country differences in survival and time trends in survival. Methods This study analyses data on liver cancer, gallbladder and extrahepatic biliary tract cancers (“biliary tract cancers”), and pancreatic cancer diagnosed in 2000–2007 from 88 CRs in 29 countries. Relative survival (RS) was estimated overall, by region, sex, age and period of diagnosis using the complete approach. Time trends in 5-year RS over 1999–2007 were also analysed using the period approach. Results The prognosis of the studied cancers was poor. Age-stand…

Cancer Researchmedicine.medical_specialtySurvivalBiliary tract cancer; Cancer registry; Europe; Pancreatic cancer; Primary liver cancer; Survival; Time trends in survival; Oncology; Cancer ResearchPopulationSocio-culturaleTime trends in survivalGastroenterologyInternal medicinePancreatic cancermedicineeducationSurvival analysiseducation.field_of_studyRelative survivalbusiness.industryGallbladderPrimary liver cancerCancerPancreatic cancerCancer registrymedicine.diseaseCancer registryEuropeBiliary tract cancer ; Cancer registry ; Europe ; Pancreatic cancer ; Primary liver cancer ; Survival ; Time trends in survivalmedicine.anatomical_structureOncologyBiliary tract cancerLiver cancerbusiness
researchProduct

P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

2021

CisplatinFirst line treatmentBiliary tract cancerOncologybusiness.industrymedicineCancer researchHematologybusinessGemcitabinemedicine.drugAnnals of Oncology
researchProduct

79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary trac…

2020

Cisplatinmedicine.medical_specialtyBiliary tract cancerbusiness.industryPlacebo-controlled studyHematologyGastroenterologyGemcitabineFirst line treatmentOncologyInternal medicinemedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).

2021

348 Background: The proportion of females in medicine is increasing (approx. 50% in medical school/workforce), but disparities in female authorship in oncology research publications exist; female corresponding authorship reportedly ranges from 7.2-39.1% in oncology clinical trials (Ludmir et al 2019). This study aimed to describe and assess factors associated with female first and senior authorship in later phase systemic clinical trials in BTC and to identify any changes over time. Methods: Embase/Medline were used to identify final primary trial publications in BTC (2000-2020) (excluding phase I (PI) (expected to move to later phase), mixed tumour site trials, reviews, editorials and tri…

Clinical trialCancer Researchmedicine.medical_specialtyBiliary tract cancerOncologybusiness.industryFamily medicineWorkforceRepresentation (systemics)Medical schoolMedicinebusinessJournal of Clinical Oncology
researchProduct

Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome : A retrospective analysis from the Finnish National Lynch Syndrom…

2023

IntroductionPatients with Lynch syndrome (LS) have an increased lifetime risk of pancreatic cancer (PC) and biliary tract cancer (BTC). These cancers have a notoriously pessimistic prognosis due to late diagnosis and limited therapeutic options. There are limited data based on small cohorts reviewing PC and BTC in LS patients.MethodsIn this retrospective study of the Lynch Syndrome Registry of Finland (LSRFi), records of genetically verified LS patients diagnosed with PC or BTC between 1982 and 2020 were analyzed.ResultsThirty-nine patients were included: tumor(s) were in the pancreas in 26 patients, in the biliary tract in 10, and in the ampulla of Vater in three. A pathogenic germline var…

Lynch syndrome (LS)Cancer Researchhereditary nonpolyposis colon cancermicrosatellite instability (MSI)3122 Cancerspancreatic cancerPancreatic cancer3121 Internal medicinemikrosatelliititLynch syndromeOncologyhereditary nonpolyposis colon cancer (HNPCC)biliary tract cancerBiliary tract cancermicrosatellite instabilityLynchin oireyhtymähaimasyöpäpaksusuolisyöpä
researchProduct

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of …

2006

Abstract Background Elderly patients have been often excluded from or underrepresented in the study populations of combination chemotherapy trials. The primary end point of this study was to determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective was to measure the time to disease progression and the survival time. Methods Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500 mg/m2 and folinic acid 250 mg/m2. All drugs were given i…

MaleOncologymedicine.medical_specialtyCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentlcsh:RC254-282Drug Administration ScheduleLEUCOVORINFolinic acidEPI-DOXORUBICINTRACT CANCERCISPLATINADVANCED ESOPHAGOGASTRIC CANCERStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointGeneticsHumansAged6S-LEUCOVORINAged 80 and overCisplatinChemotherapybusiness.industryCombination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensINFUSIONAL FLUOROURACILRANDOMIZED-TRIALOxaliplatinOxaliplatinSurvival RateRegimenOncologyFluorouracilINTENSIVE WEEKLY CHEMOTHERAPYETOPOSIDEFemaleFluorouracilbusinessResearch Articlemedicine.drug
researchProduct

Trends in the incidence and management of biliary tract cancer: a French population-based study.

2011

The trends in incidence and management of biliary tract cancer (BTC) were investigated in a well-defined French population over a 30-year period (1976-2005).Data were obtained from the Burgundy digestive cancer registry. Age-standardised incidence rates and trends in incidence were determined. Treatment and stage at diagnosis were also investigated. Five-year survival rates were calculated.Six hundred and fifteen cases of BTC were recorded. There was no significant change in BTC incidence over the 30-year period. For extrahepatic BTC age-standardised incidence rates were 1.1/100,000 for 1976-80 and 2001-2005. These rates were respectively 0.3 and 0.2/100,000 for intrahepatic BTC. The propor…

Malemedicine.medical_specialtyTime FactorsPopulationGastroenterologyBile duct cancerInternal medicineEpidemiologymedicineHumanseducationSurvival rateAgedNeoplasm Stagingeducation.field_of_studyBiliary tract cancerHepatologyRelative survivalbusiness.industryIncidence (epidemiology)Incidencemedicine.diseasePopulation based studySurvival RateBiliary Tract NeoplasmsFemaleFrancebusinessJournal of hepatology
researchProduct